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Tuberculosis control needs a complete and patient-centric 
solution
Whether it is mobile phone service or vacation travel, 
good businesses know that success depends on 
providing a complete and customer-centric solution. 
Should patients with tuberculosis not be oﬀ ered a 
complete solution that is patient-centred? After all, 
millions are aﬀ ected1 and a large market at the base-of-
the-pyramid remains unserved.
A complete and patient-centric solution will not only 
include care that meets the International Standards for 
Tuberculosis Care,2 but also be delivered with dignity 
and compassion, grounded in the reality of patients’ 
lives as they navigate the long pathway from symptoms 
to cure. Such solution-based innovation requires a 
systems-thinking approach that must place patients at 
the centre of design strategies, recognise their clinical 
and psychosocial needs, and be cost-eﬀ ective.
Are tuberculosis patients in high-burden countries 
currently getting such a patient-centric solution? Let 
us consider India, which accounts for quarter of all 
tuberculosis cases in the world.1 Whether patients in 
India seek care in the public or the private sector, they 
struggle to get a complete solution. Although the 
Revised National Tuberculosis Control Programme 
(RNTCP) has done well to reach scale and provide 
free diagnosis and treatment for patients with drug-
sensitive disease in the public sector, the programme 
falls short in making sure that all patients get screened 
for drug resistance and in ensuring adequate therapy 
for all patients with multidrug-resistant (MDR-TB) and 
extensively drug-resistant tuberculosis. Of the estimated 
64 000 cases of MDR-TB in 2012, only 17 373 cases were 
diagnosed under the RNTCP.1 
The diagnostic infrastructure in the public sector 
relies mainly on sputum smear microscopy that cannot 
detect drug resistance. It is only when patients fail to 
get better on standard treatment, or have recurrence 
of tuberculosis, that they get screened for MDR-TB, 
resulting in morbidity, continued transmission, and 
movement of patients from the public to the private 
sector. Recognising these problems, the RNTCP is 
actively scaling up capacity to diagnose and treat MDR-
TB.3 If adequately funded and successful, these initiatives 
should improve patient experience in the public sector.
But the stark reality of tuberculosis in India is that 
50% of all cases are managed in the private sector,4 
where the quality of tuberculosis care is suboptimal with 
inaccurate diagnosis,5 non-standard drug prescriptions,6 
and limited eﬀ ort to ensure treatment adherence.7 
Also, private practitioners often do not screen for drug 
resistance and empirical antibiotic abuse is rampant.8 All 
this means that drug resistance can emerge or worsen, 
with poor outcomes.8 Lastly, out-of-pocket expenditure 
in the private sector can be catastrophic.9
Are there examples of initiatives that address the 
above systemic problems? Operation ASHA is a non-
governmental organisation that extends the RNTCP 
model, and uses public sector diagnostics and drugs to 
orchestrate a solution by establishing community-based 
treatment centres and ensuring adherence using local 
community providers and partners.10 It also leverages 
biometrics to increase eﬃ  ciency and eﬀ ectiveness. It relies 
on donors and the public sector for funding. This social 
enterprise model, however, does not oﬀ er a solution to 
patients who seek care in the private sector. World Health 
Partners is a donor-supported social marketing and social 
franchising model that delivers aﬀ ordable reproductive 
and primary care (including tuberculosis) in underserved 
rural areas, by leveraging local entrepreneurs and 
informal providers and by connecting them to the formal 
For Operation ASHA see
http://www.opasha.org/
For World Health Partners see 
http://worldhealthpartners.org/
Figure: A patient with drug-resistant tuberculosis in India
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sector and specialists via telemedicine.11 The Initiative 
for Promoting Aﬀ ordable, Quality TB tests (IPAQT), a 
coalition of more than 60 private laboratories, supported 
by non-proﬁ ts such as the Clinton Health Access 
Initiative, has increased the availability and aﬀ ordability 
of WHO-endorsed tuberculosis tests.12 Although IPAQT is 
addressing the problem of suboptimal diagnosis, it does 
not cover treatment.
RNTCP recently announced “universal access to quality 
diagnosis and treatment for all tuberculosis patients 
in the community” as its goal in the new National 
Strategic Plan.3 Recognising the need to leverage the 
private sector in developing a solution, the plan includes 
engagement of the private sector using “public private 
interface agencies” to enlist, sensitise, incentivise, and 
monitor diagnosis and treatment by private providers, 
to provide patients’ cost oﬀ sets such as subsidised 
diagnostics and free drugs to privately treated patients, 
and improve case notiﬁ cations to the RNTCP. Ongoing 
pilot projects in Mumbai and Patna should inform 
policies for reﬁ nements and scale-up of this model.
Outside of India, Operation ASHA is now replicating its 
model in Cambodia. In Bangladesh, BRAC‘s tuberculosis 
programme with shasthya shebikas has been successful 
in the public sector.13 This model is now creating linkages 
with private providers. Additionally, they have created 
partner ships with garment industry owners in export 
processing zones that provide factory workers with better 
access to tuberculosis diagnosis and treatment using 
BRAC’s infrastructure.
With donor support, Interactive Research and 
Development and partners are expanding access to Xpert 
MTB/RIF (Cepheid Inc, CA, USA), a WHO-endorsed test, in 
the private sector in Dhaka, Jakarta, and Karachi, through 
mass verbal screening in private clinic waiting rooms, and 
referrals for computer-aided digital X-ray diagnosis.14 This 
model includes management of comorbid conditions 
such as diabetes and chronic obstructive pulmonary 
disease, to generate revenue for this social enterprise.
All these models are promising, but the goal of 
a complete, patient-centric solution is still elusive. 
Continued innovation in the development of scalable, 
sustainable, and replicable business models to provide 
such solutions is crucial. To improve accessibility and 
aﬀ ordability, many of the models will depend on 
community workers and coordinators, underscoring the 
need for well designed strategies for their recruitment, 
training, incentivisation, and performance management. 
Information and communications technologies will also 
be crucial for success.
Solution-centric approaches have shown promise 
in several other base-of-the-pyramid contexts, from 
aﬀ ordable eye care to artiﬁ cial limbs.15 By using product 
and process innovations, often with community 
champions, these models have shown that it is possible 
to serve base-of-the-pyramid market needs eﬀ ectively 
and eﬃ  ciently and with compassion and dignity. 
Individuals with tuberculosis deserve nothing less.
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